Advertisement

Assay of tipranavir capsules by a simple stability-indicating LC–UV method and cytotoxicity study of degraded samples

  • Leila P. Somavilla
  • Matheus W. Lago
  • Patrícia O. Barth
  • Daniele R. Nogueira-Librelotto
  • Clarice M. B. Rolim
  • Andréa I. H. AdamsEmail author
Original Paper
  • 14 Downloads

Abstract

Tipranavir (TPV) is a protease inhibitor (PI) specially recommended for treatment-experienced patients who are resistant to other PI drugs. It was approved by FDA in 2005, but, until now, it has not been included in any official compendia. The objective of this study is to develop and validate a simple LC–UV method to assay TPV capsules, and to study the cytotoxicity of TPV and degraded samples over the cell viability. The optimized conditions were C8 Phenomenex® column (Luna®, 150 mm × 4.6 mm, 5 µm); mobile phase composed by methanol, acetonitrile, and acidified water pH 3.5 (40:31:29); flow rate 1.0 mL min−1 and detection at 254 nm. The cytotoxic effects of non-degraded and degraded TPV samples were evaluated in 3T3 cells by means of MTT viability assay. The method was linear in the range of 10–100 µg mL−1 (r = 0.9999) and specific, even in the presence of degradation products and impurities. The method showed suitable accuracy (mean recovery 100.02%), precision (RSD < 1.10%), and a two-level full factorial design indicated the robustness of the method. The degraded samples exhibited cytotoxicity patterns similar to TPV under controlled conditions. The method developed is appropriate for quality control of TPV capsules and stability studies.

Keywords

Tipranavir Cytotoxicity Factorial design Stability Validation 

Notes

Acknowledgements

This research was supported by Project 459626/2014-0 of the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil). Cristalia (Brazil) donated the tipranavir reference substance and Hospital Universitário de Santa Maria (HUSM) provided the samples. Leila Paula Somavilla and Matheus Wagner Lago would like to thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001 (Brazil) for the Master’s fellowship.

References

  1. Alsante K, Ando A, Brown R, Ensing J, Hatajik T, Kong W, Tsuda Y (2007) The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev 59(1):29–37.  https://doi.org/10.1016/j.addr.2006.10.006 CrossRefGoogle Scholar
  2. Busacca CA, Campbell S, Saha A, Lorenz JC, Grozinger K, Jones PJ, Grinberg N, Shen S, Lee H, Qiu F, Granger A, Yuabova Z, Norwood D, Senanayake CH (2005) Structure elucidation and total synthesis of a unique group of trace impurities in Tipranavir® drug product. Magn Reson Chem 43(12):1032–1039.  https://doi.org/10.1002/mrc.1672 CrossRefGoogle Scholar
  3. Chen S, Dudhedia MS, Wang Z, Darrington RT, Tamblyn T, Smoliga JA, Jones PJ, Krill SL (2009) Drug-excipient complexation in lipid based delivery systems: an investigation of the tipranavir-1,3-dioctanolyglycerol complex. J Pharm Sci 98:1732–1743.  https://doi.org/10.1002/jps.21542 CrossRefGoogle Scholar
  4. Choi SO, Rezk NL, Kashuba ADM (2007) High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J Pharm Biomed Anal 43(4):1562–1567.  https://doi.org/10.1016/j.jpba.2006.11.017 CrossRefGoogle Scholar
  5. Crommentuyn KML, Rosing H, Hillebrand MJX, Huitema ADR, Beijnen JH (2004) Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B 804(2):359–367.  https://doi.org/10.1016/j.jchromb.2004.01.041 CrossRefGoogle Scholar
  6. D’Avolio A, Sciandra M, Siccardi N, Baietto L, Requena DG, Bonora S, Di Perri G (2007) A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J Chromatogr B 848(2):374–378.  https://doi.org/10.1016/j.jchromb.2006.10.030 CrossRefGoogle Scholar
  7. D’Avolio A, Simiele M, Siccardi M, Baietto L, Sciandra M, Oddone V, Stefani FR, Agati S, Cusato J, Bonora S, Di Perri G (2011) A HPLC–MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J Pharm Biomed Anal 54(4):779–788.  https://doi.org/10.1016/j.jpba.2010.10.011 CrossRefGoogle Scholar
  8. Dailly E, Reliquet V, Victorri-Vigneau C, Raffi F, Jolliet P (2006) A simple high performance liquid chromatography assay for monitoring plasma concentrations of tipranavir in HIV infected patients. J Chromatogr B 832(2):317–320.  https://doi.org/10.1016/j.jchromb.2006.02.004 CrossRefGoogle Scholar
  9. Dejaegher B, Heyden YV (2007) Experimental designs and their recent advances in set-up, data interpretation, and analytical applications. J Chromatogr A 1158:138–157.  https://doi.org/10.1016/j.chroma.2007.02.086 CrossRefGoogle Scholar
  10. Djerada Z, Feliu C, Tournois C, Vautier D, Binet L, Robinet A, Marty H, Gozalo C, Lamiable D, Millart H (2013) Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC–MS/MS technology. J Pharm Biomed Anal 86:100–111.  https://doi.org/10.1016/j.jpba.2013.08.002 CrossRefGoogle Scholar
  11. Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D (2006) Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 43(10):1337–1346.  https://doi.org/10.1086/508353 CrossRefGoogle Scholar
  12. Giraud E, Rey E, Tréluyer JM, Pons G, Jullien V (2006) Quantification of tipranavir in human plasma by high-performance liquid chromatography with UV detection. J Chromatogr B 830(1):86–90.  https://doi.org/10.1016/j.jchromb.2005.10.024 CrossRefGoogle Scholar
  13. Görög S (2003) Chemical and analytical characterization of related organic impurities in drugs. Anal Bioanal Chem 377:852–862.  https://doi.org/10.1007/s00216-003-2140-6 CrossRefGoogle Scholar
  14. ICH Harmonised Tripartite Guideline (2005) Validation of analytical procedures: text and methodology, Q2 R1. In: International conference on harmonization geneva swizerland. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 25 Mar 2019
  15. Keil K, DiFrancesco R, Morse GD (2006) Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array. Ther Drug Monit 28(4):512–516CrossRefGoogle Scholar
  16. Lago MW, Friedrich ML, Iop GD, Souza TB, Mello PA, Adams AIH (2018) Capillary zone electrophoresis method to assay tipranavir capsules and identification of oxidation product and organic impurity by quadrupole-time of flight mass spectrometry. Talanta 181:182–189.  https://doi.org/10.1016/j.talanta.2018.01.012 CrossRefGoogle Scholar
  17. Luna B, Townsend ML (2007) Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther 29:2309–2318.  https://doi.org/10.1016/j.clinthera.2007.11.007 CrossRefGoogle Scholar
  18. Martin J, Deslandes G, Dailly E, Renaud C, Reliquet V, Raffi F, Jolliet P (2009) A liquid chromatography–tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. J Chromatogr B 877(27):3072–3082.  https://doi.org/10.1016/j.jchromb.2009.07.031 CrossRefGoogle Scholar
  19. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–63CrossRefGoogle Scholar
  20. Quaranta S, Woloch C, Paccou A, Giocanti M, Solas C, Lacarelle B (2009) Validation of an electrospray ionization LC–MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Ther Drug Monit 31(6):695–702.  https://doi.org/10.1097/FTD.0b013e3181c05adf CrossRefGoogle Scholar
  21. Rebiere H, Mazel B, Civade C, Bonnet PA (2007) Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. J Chromatogr B 850(1–2):376–383.  https://doi.org/10.1016/j.jchromb.2006.12.007 CrossRefGoogle Scholar
  22. Rezk NL, Crutchley RD, Yeh RF, Kashuba ADM (2006) Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic. Drug Monit Ther Drug Monit 28(4):517–525CrossRefGoogle Scholar
  23. Satyanarayana PVV, Madhavi AS (2012a) A novel RP-HPLC method for the quantification of tipranavir in formulations. IJAPBC 1(4):516–521Google Scholar
  24. Satyanarayana PVV, Madhavi AS (2012b) New spectrophotometric methods for the quantitative estimation of tipranavir in formulations. Experiment 2(1):48–54Google Scholar
  25. Shabir GA (2003) Validation of high-performance liquid chromatographic methods for pharmaceutical analysis: understanding the differences and similarities between the requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference. J Chromatogr A 987(1–2):57–66.  https://doi.org/10.1016/S0021-9673(02)01536-4 CrossRefGoogle Scholar
  26. Simiele M, Ariaudo A, De Nicolò A, Favata F, Ferrante M, Carcieri C, Bonora S, Di Perri G, D’Avolio A (2017) UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. J Pharm Biomed Anal 138:223–230.  https://doi.org/10.1016/j.jpba.2017.02.002 CrossRefGoogle Scholar
  27. ter Heine R, Davids M, Rosing H, van Gorp ECM, Mulder JW, van der Heide YT, Beijnen JH, Huitema ADR (2009) Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 877(5–6):575–580.  https://doi.org/10.1016/j.jchromb.2009.01.011 CrossRefGoogle Scholar
  28. Watson DG (2005) Pharmaceutical analysis: a textbook for pharmacy students and pharmaceutical chemists. Churchill Livingstone, New YorkGoogle Scholar
  29. Wensing AMJ, Van Maarseveen NM, Nijhuis M (2010) Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 85(1):59–74.  https://doi.org/10.1016/j.antiviral.2009.10.003 CrossRefGoogle Scholar
  30. Yoshioka S, Stella VJ (2002) Stability of drugs and dosage forms. Kluwer Academic Publishers, New YorkGoogle Scholar

Copyright information

© Institute of Chemistry, Slovak Academy of Sciences 2019

Authors and Affiliations

  1. 1.Programa de Pós-Graduação em Ciências FarmacêuticasUniversidade Federal de Santa MariaSanta MariaBrazil
  2. 2.Departamento de Farmácia IndustrialUniversidade Federal de Santa MariaSanta MariaBrazil

Personalised recommendations